...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials.
【24h】

Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials.

机译:将化学疗法添加到放射治疗中,会根据非小细胞肺癌(NSCCL)中的细胞类型改变失败模式:放射治疗肿瘤学组(RTOG)试验的分析。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the influence of cell type within non-small cell carcinoma of lung (NSCCL) on failure patterns when chemotherapy (CT) is combined with radiation therapy (RT). METHODS AND MATERIALS: Data from 4 RTOG studies including 1415 patients treated with RT alone, and 5 RTOG studies including 350 patients also treated with chemotherapy (RT + CT) were analyzed. Patterns of progression were evaluated for squamous cell carcinoma (SQ) (n = 946), adenocarcinoma (AD) (n = 532) and large cell carcinoma (LC) (n = 287). RESULTS: When treated with RT alone, SQ was more likely to progress at the primary site than LC (26% vs. 20%, p = 0.05). AD and LC were more likely to progress in the brain than SQ (20% and 18% vs. 11%, p = 0.0001 and 0.011, respectively). No differences were found in intrathoracic and distant metastasis by cell type. When treated with RT + CT, AD was less likely to progress at the primary than either SQ or LC (23% vs. 34% and 40%, respectively; p = 0.057 and 0.035). AD was more likely than SQ to metastasize to the brain (16% vs. 8%, p = 0.03), and other distant sites (26% vs. 14%,p = 0.019). No differences were found in intrathoracic metastasis. LC progressed at the primary site more often with RT + CT than with RT alone (40% vs. 20%, p = 0.036). Death with no clinical progression was more likely with SQ than AD or LC for RT alone and RT + CT (p < 0.01). Brain metastasis was altered little by the addition of CT, but other distant metastases were significantly decreased (p < 0.001) in all cell types by the addition of CT. CONCLUSION: CT, although effective in reducing distant metastasis in all types of NSCCL, has different effects on the primary tumor by cell type, and has no effect on brain metastasis or death with no progression. Different treatment strategies should be considered for the different cell types to advance progress with RT + CT in NSCCL.
机译:目的:评估化学疗法(CT)与放射疗法(RT)结合使用时,非小细胞肺癌(NSCCL)细胞类型对失败模式的影响。方法和材料:分析了4项RTOG研究(包括1415例仅接受RT治疗的患者)和5项RTOG研究(包括350例也接受了化疗(RT + CT)治疗)的数据。评估鳞状细胞癌(SQ)(n = 946),腺癌(AD)(n = 532)和大细胞癌(LC)(n = 287)的进展模式。结果:单独接受放疗时,SQ较LC更可能在原发部位进展(26%vs. 20%,p = 0.05)。与SQ相比,AD和LC在大脑中发展的可能性更大(分别为20%和18%与11%,p = 0.0001和0.011)。按细胞类型,胸内和远处转移均无差异。当用RT + CT治疗时,AD的原发进展较SQ或LC少(分别为23%,34%和40%; p = 0.057和0.035)。与SQ相比,AD更有可能转移到大脑(16%比8%,p = 0.03)和其他远处部位(26%比14%,p = 0.019)。胸内转移无差异。 RT + CT比单独使用RT时,LC在原发部位的进展更为频繁(40%vs. 20%,p = 0.036)。对于单独的RT和RT + CT,SQ比AD或LC更有可能没有临床进展的死亡(p <0.01)。通过添加CT,脑转移几乎没有改变,但是通过添加CT,在所有细胞类型中其他远处转移明显减少了(p <0.001)。结论:CT尽管能有效减轻所有类型的NSCCL的远处转移,但按细胞类型对原发肿瘤的作用不同,对脑转移或死亡无影响,无进展。对于不同的细胞类型,应考虑不同的治疗策略,以促进NSCCL中RT + CT的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号